Mycoses in AIDS PatientsH. van den Bossche, Hugo Vanden Bossche The World Health Organization estimates that at least five million people worldwide are infected with human immunodeficiency virus (HIV) Of these about 100,000 are in Asia and Oceania, 500,000 in Europe, 2 million in the Americas and 2.5 million in Africa (Mann, 1989). The acquired immunodeficiency syndrome is characterized by a derangement in cell-mediated immunity leading to opportunistic infections with for example Mycobacterium spp., Candida spp., Cryptococcus neoformans, Pneumocystis carinii, Toxoplasma gondii and Cryptosporidium. The third symposium on "Topics in Mycology" brought together 265 experts from 32 countries to discuss the epidemiology, immmunological and pathogenetic aspects of AIDS and its opportunistic infections in general and fungal infections in particular. Pneumocystis carinii pneumonia is by far the commonest opportunistic infection in AIDS patients. The nature and classification of P. carinii is still controversial. In search for its true taxonomic affinities an introductory paper formulates a number of key questions. Candidosis is another frequent opportunistic infection. A number of papers discuss the possibility that selective pressures may operate on Candida albicans within the AIDS population and influence its nature: this might have an impact on prophylaxis and curative and/or suppressive therapy. |
Contents
Epidemiology of AIDS and Its Opportunistic Infections | 3 |
Mycoses in AIDS Patients An Overview 27 | 27 |
A Nomadic Taxon | 55 |
Copyright | |
16 other sections not shown
Other editions - View all
Mycoses in AIDS Patients Geert Cauwenbergh,Édouard Drouhet,Donald W R MacKenzie No preview available - 1990 |
Mycoses in AIDS Patients Geert Cauwenbergh,Edouard Drouhet,Donald W.R. Mackenzie,Jan Van Cutsem,Hugo Vanden Bossche No preview available - 2011 |
Common terms and phrases
acquired immune acquired immunodeficiency syndrome activity AIDS patients amphotericin antibodies antifungal agents antigen aspergillosis Aspergillus asymptomatic autopsy azole Candida albicans candidemia candidiasis candidosis capsulatum catheter Cauwenbergh CD4+ cells chronic Clin clinical coccidioidal infection coccidioidomycosis cryptococcal antigen cryptococcal meningitis cryptococcosis Cryptococcus neoformans Cutsem deficiency syndrome dermatitis Dermatol dermatophytes diagnosis disease Dismukes disseminated histoplasmosis dose Drouhet drug effective endemic ergosterol esophageal evaluable factors fluconazole fungal infections fungi fungus Galgiani gattii glabrata Graybill histoplasmosis HIV infection homosexual human immunodeficiency virus immunological inhibitors isolates itraconazole ketoconazole lesions lymphocytes macrophages marneffei mg per day Microbiol months mucosal Mycology mycoses Mycoses in AIDS non-AIDS opportunistic infections oral candidosis patients with acquired patients with AIDS pharmacokinetic Pityrosporum Pneumocystis carinii pre+ 30 prevalence protein pulmonary relapse reported response seborrhoeic seborrhoeic dermatitis serotype serum skin sporotrichosis sterols T-cell Table therapy tissue treatment triazole Vanden Bossche viral vitro yeast
References to this book
Biologically Active Natural Products: Pharmaceuticals Stephen J. Cutler,Horace G. Cutler Limited preview - 1999 |